Kimberly-Clark's Acquisition of Kenvue Faces Uncertainty Amid Weakening Sales and Legal Concerns.

Thursday, Nov 6, 2025 3:20 am ET1min read

Kimberly-Clark's stock fell 1.7% to $100.55 as investors questioned the company's decision to acquire Kenvue, which has weakening sales and potential legal liabilities related to Tylenol and talc. The deal requires shareholder approval from both companies.

Kimberly-Clark's Acquisition of Kenvue Faces Uncertainty Amid Weakening Sales and Legal Concerns.

Comments



Add a public comment...
No comments

No comments yet